Press Releases April 14, 2026 08:00 PM

BOSS Zhipin's Ongoing Share Repurchases Surpass RMB862 Million in 2026

KANZHUN LIMITED intensifies share repurchase program with over RMB862 million spent in 2026 to enhance shareholder value.

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, operating under the brand BOSS Zhipin, announced that it has exceeded RMB862 million in share repurchases in 2026, including a recent buyback of 587,254 shares worth RMB27.2 million as part of its ongoing program aimed at returning value to shareholders.

BOSS Zhipin's Ongoing Share Repurchases Surpass RMB862 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has spent over RMB862 million on share repurchases so far in 2026.
  • The company repurchased 587,254 shares worth RMB27.2 million on April 14, 2026.
  • The share buyback program signals strong commitment to enhancing shareholder value amid market activities.

BEIJING, April 15, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB27.2 million to repurchase 587,254 ordinary shares on April 14. Year-to-date in 2026, the Company has deployed over RMB862 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Market volatility could impact the effectiveness and timing of ongoing share repurchases, affecting capital allocation efficiency.
  • Economic or regulatory changes in China or US markets may influence company performance and investor confidence.
  • Overemphasis on share buybacks might divert funds from other growth opportunities or operational investments.

More from Press Releases

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026 Traws Pharma Provides Regulatory Update on Influenza Program Jun 12, 2026 Heartland Express, Inc. Declares Regular Quarterly Dividend Jun 12, 2026